SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC lifted its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 254.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 580,938 shares of the company’s stock after buying an additional 416,942 shares during the period. Jane Street Group LLC’s holdings in SpringWorks Therapeutics were worth $28,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the stock. Headlands Technologies LLC acquired a new stake in SpringWorks Therapeutics in the 4th quarter valued at approximately $74,000. Strs Ohio acquired a new stake in SpringWorks Therapeutics in the 4th quarter valued at approximately $102,000. SG Americas Securities LLC acquired a new stake in SpringWorks Therapeutics in the 4th quarter valued at approximately $157,000. CANADA LIFE ASSURANCE Co increased its holdings in SpringWorks Therapeutics by 20.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock valued at $220,000 after purchasing an additional 754 shares during the last quarter. Finally, Financial Security Advisor Inc. purchased a new position in SpringWorks Therapeutics in the 1st quarter valued at approximately $246,000.

SpringWorks Therapeutics Trading Down 2.2 %

Shares of SWTX stock traded down $0.82 on Wednesday, reaching $35.91. 497,410 shares of the stock were exchanged, compared to its average volume of 970,513. The business’s 50 day moving average price is $38.65 and its 200 day moving average price is $43.45. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -6.99 and a beta of 0.78. SpringWorks Therapeutics, Inc. has a twelve month low of $18.00 and a twelve month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Thursday, May 2nd. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.01). The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $12.07 million. The company’s quarterly revenue was up 2000.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.18) EPS. Equities research analysts forecast that SpringWorks Therapeutics, Inc. will post -4.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SWTX. HC Wainwright reaffirmed a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research report on Friday, May 31st. Wedbush reaffirmed an “outperform” rating and set a $75.00 price objective (up previously from $70.00) on shares of SpringWorks Therapeutics in a research report on Thursday, May 2nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $68.83.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.